Bio

Michael Yu is a corporate partner at Cooley. His practice focuses on initial public offerings and other equity capital markets transactions on the Hong Kong Stock Exchange, pre-IPO investments, public takeovers and listing rules and securities regulations compliance. Michael has actively participated in the strategic initiative by HKEX to attract new-economy companies to list in Hong Kong. In particular, he advised Asymchem on its US$979 million IPO and listing on HKEX which is the largest healthcare HK IPO in 2021. He has also advised Ascletis Pharma on its US$400 million HK IPO in 2018, the first pre-revenue biotech IPO on HKEX under its new listing regime for companies from emerging and innovative sectors. He has also advised a number of new-economy companies, including companies in biotech and internet sectors, on their HK IPOs. Michael was recognized in IFLR1000 2019 and 2021 as a Notable Practitioner for equity capital markets work. Michael is fluent in English and a native Mandarin speaker.